Home
Alembic Pharmaceuticals Ltd 52 Week Low

Alembic Pharmaceuticals Ltd
NSE: APLLTD
YEARLOW
Key Highlights
- The 52 Week Low of Alembic Pharmaceuticals Ltd is ₹ 725.6 as of 11 Apr 25 .
Company Fundamentals for Alembic Pharmaceuticals Ltd
Market Price of Alembic Pharmaceuticals Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
11 Apr 2025 | 847.4 |
09 Apr 2025 | 839.95 |
08 Apr 2025 | 850 |
07 Apr 2025 | 844.1 |
04 Apr 2025 | 881.8 |
03 Apr 2025 | 888.9 |
02 Apr 2025 | 885.2 |
01 Apr 2025 | 897.55 |
28 Mar 2025 | 929.25 |
27 Mar 2025 | 930.9 |
Asset Value vs Market Value of Alembic Pharmaceuticals Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Historical Revenue of Alembic Pharmaceuticals Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Alembic Pharmaceuticals Ltd
Historical Net Profit of Alembic Pharmaceuticals Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd News Hub
Alembic Pharma receives USFDA approval for Dabigatran Etexilate Capsules
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) f
Read more
13 Aug 24
Alembic Pharma gets US FDA nod for anticoagulant Dabigatran
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa
Read more
13 Aug 24
Alembic Pharmaceuticals Ltd leads losers in 'A' group
Steel Authority of India Ltd, IFCI Ltd, Coffee Day Enterprises Ltd and Orient Cement Ltd are among t
Read more
09 Aug 24
Alembic Pharma Q1 PAT rises 12% YoY to Rs 135 cr
Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 J
Read more
08 Aug 24